



# Clinical Factors Associated with C - Reactive Protein in Chronic Spinal Cord Injury

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters

Citation	Goldstein, Rebekah, Palak Walia, Merilee Teylan, Antonio A. Lazzari, Carlos G. Tun, Jaime E. Hart, and Eric Garshick. 2017. "Clinical Factors Associated with C - Reactive Protein in Chronic Spinal Cord Injury." <i>Spinal cord</i> :10.1038/sc.2017.81. doi:10.1038/sc.2017.81. <a href="http://dx.doi.org/10.1038/sc.2017.81">http://dx.doi.org/10.1038/sc.2017.81</a> .
Published Version	<a href="https://doi.org/10.1038/sc.2017.81">doi:10.1038/sc.2017.81</a>
Citable link	<a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:35015018">http://nrs.harvard.edu/urn-3:HUL.InstRepos:35015018</a>
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>



## Clinical Factors Associated with C - Reactive Protein in Chronic Spinal Cord Injury

Rebekah Goldstein, MPH<sup>1</sup>, Palak Walia, BS<sup>1</sup>, Merilee Teylan, MPH<sup>1</sup>, Antonio A. Lazzari, MD, CCD, PhD<sup>2</sup>, Carlos G. Tun, MD<sup>3</sup>, Jaime E. Hart, ScD<sup>4,5,6</sup>, and Eric Garshick, MD, MOH<sup>5,6,7</sup>

<sup>1</sup>Research and Development Service, VA Boston Healthcare System, Boston, MA

<sup>2</sup>Division of Primary Care and Rheumatology Section, VA Boston Healthcare System, Boston, MA, Boston University School of Medicine, Boston, MA

<sup>3</sup>Department of Physical Medicine and Rehabilitation, VA Boston Healthcare System, Boston, MA

<sup>4</sup>Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA

<sup>5</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA

<sup>6</sup>Harvard Medical School, Boston, MA

<sup>7</sup>Pulmonary, Allergy, Sleep, and Critical Care Medicine Section, Medical Service, VA Boston Healthcare System, Boston, MA

### Abstract

**Study Design**—Cross-sectional study.

**Objectives**—Determine clinical factors associated with plasma C-reactive protein (CRP) in persons with chronic spinal cord injury (SCI).

**Setting**—Veterans Affairs Medical Center in Boston, MA.

**Methods**—Participants provided a blood sample, completed a respiratory health questionnaire, and underwent dual x-ray absorptiometry (DXA) to assess total and regional body fat. Linear regression models were used to assess cross-sectional associations with plasma CRP.

**Results**—In multivariable models, factors associated with a higher CRP included a greater BMI, urinary catheter use, a respiratory illness in the past week, and non-white race. Mean CRP also increased with decreasing mobility (motorized wheel chair > hand propelled wheel chair > walk with an assistive device > walk independently). Results were similar when adjusting for % android, gynoid, trunk, or total fat mass in place of BMI. Level and completeness of SCI was not associated with CRP in multivariable models.

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Correspondence: Eric Garshick, MD, MOH, Pulmonary, Allergy, Sleep, and Critical Care Medicine Section, VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132, Phone: (857) 203-5536, Fax: (857) 203-5670, Eric.Garshick@va.gov.

**Conflict of interest:** The authors report no conflict of interest.

**Conclusions**—Clinical characteristics common in chronic SCI are associated with plasma CRP. These factors are more important than level and completeness of SCI and some are potentially modifiable.

### Keywords

C-reactive protein; body fat; spinal cord injury

---

## Introduction

Chronic spinal cord injury (SCI) is characterized by clinical factors that promote systemic inflammation including reduced mobility,<sup>1-5</sup> accumulation of central fat,<sup>6-8</sup> and recurrent infections.<sup>9-10</sup> The linkage between systemic inflammation as assessed by C-reactive protein (CRP) and the development of atherosclerosis and coronary heart disease is well established.<sup>11</sup> As individuals with SCI age, they are at increased risk for developing cardiovascular disease,<sup>12</sup> which has become a major cause of mortality in the SCI population.<sup>13-18</sup>

Although elevated CRP levels have previously been described in chronic SCI,<sup>19-22</sup> to date, there has been a limited description of clinical factors that contribute. Slowly healing pressure ulcers in 34 men with SCI,<sup>9</sup> urinary tract infections in 37 men,<sup>10</sup> tetraplegia compared to paraplegia in 69 men and women,<sup>23</sup> and greater fat mass and body mass index (BMI) in 77 men and women have been associated with elevated CRP levels.<sup>24</sup> In a previous report in 63 individuals, we found that mobility mode, a greater BMI, heart disease, and a pressure ulcer reported in the past year, were each associated with higher circulating CRP.<sup>25</sup> A limitation of these previous reports, however, is a reduced ability to assess multiple covariates due to small sample sizes. The objective of this report is to assess the robustness of our previous findings in a new chronic SCI cohort with more than five times as many participants, as well as to assess the impact of additional factors, including fat mass assessed by dual x-ray absorptiometry (DXA) on levels of CRP.

## Methods

### Subjects

Between 8/2009 and 4/2015 we recruited 360 individuals into a study of respiratory health among individuals with chronic SCI. Participants were recruited from patients receiving care at VA Boston, from the greater Boston area through advertisement, and by direct mail to persons who had received care at Spaulding Rehabilitation Hospital, Boston University Medical Center, were members of the National Spinal Cord Injury Association, or were subscribers to New Mobility Magazine. Individuals were eligible if they were 22 years of age or older, were 1 or more years post-injury, had no other neuromuscular disease, did not have a tracheostomy, and were able to breathe without chronic ventilatory support. Participants were eligible regardless of etiology of SCI and testing was scheduled when subjects were free of acute illness. The Institutional Review Board at VA Boston Healthcare System approved the protocol and informed consent was obtained. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research.

### Neurological exam, stature, and weight

SCI level and severity was assessed by exam and medical record review.<sup>26</sup> Motor incomplete SCI included AIS C (most key muscles below the neurological level grade < 3/5) or AIS D (most muscles below the neurological level grade = 3/5). For analysis, participants were further grouped into cervical motor complete (AIS A or B) and cervical AIS C, high thoracic (T1-T6) complete (AIS A or B) and AIS C, others with T7 or below motor complete (AIS A or B) or AIS C, and all others (AIS D's). Height was obtained by measuring the body length from top of the head to the heel of the subject in a supine position. Supine length was measured in 307 (91%) and obtained by self-report in 31 (9%) when contractures precluded accurate measurement. If required, wheelchairs were weighed with and without the participant, and wheelchair weight subtracted. In 5 persons, self-report of weight was used. BMI (kg/m<sup>2</sup>) was calculated from height and weight.

### Dual x-ray absorptiometry (DXA) for % body fat

A 5<sup>th</sup> generation GE Healthcare iDXA scanner was used to assess % total body, % trunk, % android, and % gynoid fat using GE Lunar software analyzed by a certified clinical densitometrist (AAL). Daily quality assurance was performed utilizing a phantom. The trunk region was defined by cuts passing through the shoulders and extended inferiorly as close to the body as possible through the femoral necks. The lower boundary of the android region was a horizontal cut at the level of the iliac crests and the upper boundary extended upwards to 20% of the distance between the pelvis and shoulders. For the gynoid region, the upper boundary was the iliac crests and the lower boundary included the pelvis and extended downward 1.5 times the height of the android region.

### Health Questionnaire

A questionnaire based on American Thoracic Society Division of Lung Diseases ATS DLD-78<sup>27</sup> was used to obtain a history of cigarette smoking, comorbid medical diseases, and statin use. Hypertension, diabetes, and asthma were defined based on report of a diagnosis by a doctor, and chronic obstructive pulmonary disease (COPD) was defined as either doctor-diagnosed emphysema or chronic bronchitis. Heart disease was defined as treatment for "heart trouble" reported in the 10 years prior to study entry. Participants were asked to report if a chest illness kept them off work, indoors at home, or in bed in the previous one and three years, if they had had a respiratory illness in the past week, if they currently had a urinary tract infection (UTI) or a skin ulcer, or if they had experienced either in the past one and three years, how they usually passed urine, and if they received regular dental care. Usual mobility mode (more than 50% of the time) was ascertained in four categories: motorized wheelchair use, hand-propelled wheelchair use, walk with aid such as crutch or cane, or walk without assistance.

### Biochemical Analyses

Plasma samples were drawn into an EDTA tube and immediately delivered to a core blood research laboratory. The samples were centrifuged for 15 min at 2600 rpm (1459 x g) at 4°C and stored at -80°C until batch analysis. High sensitivity CRP concentrations using an immunoturbidimetric assay were determined at the Clinical & Epidemiologic Research

Laboratory, Department of Laboratory Medicine at Children's Hospital in Boston. This assay has a sensitivity of 0.03 mg/L. The day-to-day variability of the assay at concentrations of 0.91, 3.07, and 13.38 mg/L are 2.81, 1.61, and 1.1%, respectively.

### Statistical Analysis

We excluded persons without a detectable SCI level (n=3), history of stroke (n=2), incomplete data collection (n=6), inability to obtain blood (n=6), incomplete data on body composition (n=4), or without CRP results (n=1), leaving a sample size of 338 participants. There were 26 subjects who participated in our previous study (2004-2005)<sup>25</sup> who were retested. Natural log-transformation of CRP was used to meet modeling assumptions. General linear models (PROC GLM, SAS version 9.4) were used to assess determinants of natural log CRP. A Tukey adjustment was used for multiple comparisons. Trends across %-fat and BMI quartiles were assessed using the median values and trends for mobility and SCI categories assessed by assigning ordinal numbers. Variables significant in univariable models at the 0.10 level or less were included in multivariate models. We *a priori* assessed characteristics associated with infection (i.e., ulcer history) and considered effects of comorbid diseases as potential confounders.

## Results

### Participant Characteristics

Participant characteristics are presented in Table 1 overall and by primary mobility mode. The mean  $\pm$  standard deviation age and injury duration were 54.1 $\pm$ 14.4 years and 17.3 $\pm$ 13.3 years, respectively (Table 1). The majority of participants were male (82%) and white (86%). When screened by questionnaire at the time of testing, a mild cold or other respiratory illness was reported by 26 persons (7.7%) in the past week. A history of skin ulcers, urinary tract infections, and catheter use were more common among motorized and hand-propelled wheelchair users. There were 83 people (25%) with CRP levels <1 mg/L (defined as low cardiovascular risk),<sup>11</sup> 105 (31%) with CRP levels of 1-3mg/L, and 150 (44%) with CRP levels of >3 mg/L). There were 54 (16%) with very high CRP levels (>10mg/L). The distribution of natural log CRP was normally distributed (Shapiro-Wilks test W=0.996, p=0.640) and there was no evidence of outliers.

### Univariable associations

In univariable models, age, sex, injury duration, smoking status and pack-years of smoking, sex, statin use, dental care, and comorbidities were not associated with CRP (Table 2). Both mobility mode and level and completeness of SCI were statistically significantly associated with CRP, with the highest CRP levels observed among motorized wheelchair users and among cervical motor complete and AIS C SCI with a significant linear trend across mobility and SCI level and completeness categories (Table 2). Persons who reported a current skin ulcer or a UTI or reported either in the past one and three years had higher CRP levels compared to persons without these conditions. Persons who used a condom catheter, a chronic indwelling catheter, or used periodic catheterization had CRP values that were not statistically significantly different from one another (p=0.551-0.999), but each was statistically significantly different from participants who did not use a catheter. Therefore,

catheter use was considered as a dichotomous variable. Catheter use was strongly associated with report of a current UTI as 21 out of the 25 persons with a current UTI used a catheter. Persons who reported a respiratory illness (4.10; 95%CI: 2.28, 5.01mg/L) in the past week had greater CRP values compared to persons without an illness (2.54; 95%CI: 2.14, 2.97 mg/L,  $p=0.096$ ). Participants who were self-identified as being white had lower CRP values compared to non-white participants ( $p=0.038$ ). Each measure of adiposity was also statistically significantly positively associated with CRP, with a significant trend across quartiles (Table 3).

### Multivariable associations

Due to the high level of collinearity between the DXA-derived measures of adiposity (Pearson  $r=0.705-0.979$ ,  $p<0.0001$ ) and a significant correlation between these measures with BMI ( $r=0.393-0.689$ ,  $p<0.0001$ ), we created five multivariable models including each adiposity measure separately with other predictors (Table 4). Each adiposity measure (including BMI) were statistically significantly associated with CRP levels in multivariate models ( $p<0.001$ ). There was a significant positive linear trend across adiposity measure quartiles (not shown), so the continuous measures were used in the final models. Urinary catheter use also remained statistically significantly associated with CRP ( $p=0.002-0.013$ ), with a better model fit than either current UTI or UTI in the previous year. Participants with a respiratory illness in the week before testing (usually a mild cold) had significantly greater CRP levels ( $p=0.005-0.015$ ), as did those who identified as non-white ( $p=0.001-0.041$ ). In each model (Table 4), participants who reported a current ulcer had a higher CRP compared to persons without an ulcer that was not statistically significant ( $p=0.096-0.173$ ). Associations with an ulcer reported in the past year ( $p=0.254-0.450$ ) were weaker and not significant.

In four multivariable models (Table 4), there was a significant linear trend across mobility categories with CRP ( $p<0.001-0.018$ ), and a suggestive relationship in an additional model ( $p=0.069$ ). When included in these models SCI level and completeness was not a statistically significant predictor of CRP ( $p=0.554-0.974$ ).

### Effect of chronic disease

In order to account for effects of comorbid diseases on CRP as potential confounders, we individually added heart disease, diabetes, hypertension, COPD, asthma, and any obstructive lung disease (asthma or COPD) into the final multivariable models. The effects of measures of adiposity, urinary catheter, respiratory illness in the past week, current skin ulcer, race, and mobility mode did not meaningfully change (data not shown). Heart disease was significantly associated with a greater CRP ( $p=0.021-0.039$ ) in all models as was hypertension in the model that included gynoid fat ( $p=0.015$ ). Hypertension in other models ( $p=0.100-0.157$ ), diabetes ( $p=0.198-0.770$ ), COPD ( $p=0.786-0.976$ ), asthma ( $p=0.163-0.372$ ), and any obstructive lung disease (asthma or COPD) ( $p=0.305-0.440$ ) were not significantly associated with CRP.

## Discussion

In this cross-sectional study in a cohort of individuals with chronic SCI, we found that measures of adiposity (BMI, % total body fat, % trunk fat, % android fat, and % gynoid fat), mobility mode, catheter use, race, and respiratory illness in the past week were all independently associated with circulating levels of CRP. There was a strong linear association found between SCI level and CRP in univariable models ( $p < .0001$ ) that was not evident after adjustment for mobility mode. We previously reported similar results in a smaller study ( $n=63$ ) in our earlier chronic SCI cohort, indicating that these findings are reproducible in the SCI population.<sup>25</sup> The effects of clinical factors identified in multivariable models were not affected after adjustment for comorbidities that included heart disease, hypertension, diabetes, COPD, and asthma. Although heart disease history was significantly associated with a higher CRP value in multivariate models, it did not confound the relationship between the clinical factors included in the multivariable models and CRP.

Pressure ulcers and UTI's have been previously associated with an elevated CRP levels.<sup>9-10</sup> The participants in this cohort were tested when they were feeling well and were able to sit upright for study-related procedures. This likely explains why relatively few persons reported a current skin ulcer (11.2%), and its weak association with CRP in the multivariate models. Considerably more persons (25.2%) reported a skin ulcer in the past year. Similarly, few persons in our cohort reported a current UTI (7.4%), but many reported having a UTI in the past year (40.2%). Both chronic, intermittent, and condom catheter use are known correlates of chronic bacteriuria and pyuria<sup>28</sup> which is most likely responsible for the higher CRP values associated with catheter use.

We directly assessed percent fat in the android, gynoid, and trunk regions as well as total body fat by DXA scan. In SCI, due to a decrease in lean mass and increase in increase in fat mass and in central (truncal) fat,<sup>6-7,29</sup> BMI may not accurately assess adiposity.<sup>30</sup> However, we found similar effects of BMI and other measures of adiposity on CRP levels in multivariate models, most likely attributable to the high degree of correlation between the fat measures.

Our findings support the hypothesis that physiologic changes that occur following SCI attributable to decreased mobility, bladder dysfunction, and skin ulcers contribute to CRP and systemic inflammation, and therefore, potentially future risk of cardiovascular disease. Many studies in persons without SCI have found higher levels of CRP to be associated with lower levels of physical activity.<sup>1-3,31</sup> Evidence that chronic or recurrent infection may be associated with cardiovascular disease comes from positive associations between periodontal disease and carotid intima-media thickness,<sup>32</sup> and the timing of a myocardial infarction and a preceding systemic respiratory tract<sup>33</sup> or urinary tract infection<sup>34</sup> in persons without chronic SCI.

A considerable strength of this study is the use of a comprehensive standardized approach allowing the consideration of multiple factors potentially associated with CRP in a large chronic SCI cohort. Limitations includes reliance on self report of current ulcer, UTI and of chronic medical conditions. However, we have previously validated the use of self-report of



chronic medical conditions in this population.<sup>14</sup> Misclassification would make it more difficult to detect the true associations with CRP.

Our study findings support the importance of studying modifiable factors in chronic SCI that can impact on health. A longitudinal study is needed to assess relationship between factors identified, chronic elevations in CRP, and subsequent effects on cardiovascular health. Addressing modifiable factors related to obesity, reduced physical activity, and recurrent infection could potentially help in lowering the risk of cardiovascular disease among those with chronic SCI.

## Acknowledgments

Supported by VA Rehabilitation Research and Development Merit Review Grant B6618R and I01 RX000792 from the U.S. Department of Veterans Affairs Rehabilitation Research and Development Service; and NIH Grant AR059270. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

## References

1. Kaspis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. *J Am Coll Cardiol*. 2005; 45(10):1563–69. [PubMed: 15893167]
2. Nicklas BJ, You T, Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. *CMAJ*. 2005; 172(9):1199–1209. [PubMed: 15851714]
3. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. *Scand J Med Sci Sports*. 2007; 17(5):580–87. [PubMed: 17076827]
4. Penninx BW, Kritchevsky SB, Newman AB, Nicklas BJ, Simonsick E, Rubin S, et al. Inflammatory markers and incident mobility limitation in the elderly. *J Am Geriatr Soc*. 2004; 52(7):1105–13. [PubMed: 15209648]
5. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. *J Am Geriatr Soc*. 1999; 47(6):639–46. [PubMed: 10366160]
6. Spungen AM, Adkins RH, Stewart CA, Wang J, Pierson RN Jr, Waters RL, et al. Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. *J Appl Physiol*. 2003; 95(6):2398–2407. [PubMed: 12909613]
7. Maggioni M, Bertoli S, Margonato V, Merati G, Veicsteinas A, Testolin G. Body composition assessment in spinal cord injury subjects. *Acta Diabetol*. 2003; 40(Suppl1):S183–86. [PubMed: 14618468]
8. Edwards LA, Bugaresti JM, Buchholz AC. Visceral adipose tissue and the ratio of visceral to subcutaneous adipose tissue are greater in adults with than in those without spinal cord injury, despite matching waist circumferences. *Am J Clin Nutrition*. 2008; 87:600–07. [PubMed: 18326597]
9. Segal JL, Gonzales E, Yousefi S, Jamshidipour L, Brunnemann SR. Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. *Arch Phys Med Rehabil*. 1997; 78(1):44–47. [PubMed: 9014956]
10. Frost F, Roach MJ, Kushner I, Schreiber P. Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. *Arch Phys Med Rehabil*. 2005; 86(2):312–17. [PubMed: 15706560]
11. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. *Circulation*. 2003 Jan 28; 107(3):499–511. [PubMed: 12551878]



12. LaVela SL, Evans CT, Prohaska TR, Miskevics S, Ganesh SP, Weaver FM. Males aging with a spinal cord injury: prevalence of cardiovascular and metabolic conditions. *Arch Phys Med Rehabil.* 2012; 93:90–5. [PubMed: 22200386]
13. DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. *Arch Phys Med Rehabil.* 1999; 80:1411–19. [PubMed: 10569435]
14. Garshick E, Kelley A, Cohen SA, Garrison A, Tun CG, Gagnon D, et al. A prospective assessment of mortality in chronic spinal cord injury. *Spinal Cord.* 2005; 43:408–16. [PubMed: 15711609]
15. Osterthun R, Post MWM, van Asbeck FWA, van Leeuwen CMC, van Koppenhagen CF. Causes of death following spinal cord injury during inpatient rehabilitation and the first five years after discharge. *Spinal Cord.* 2014; 52:483–88. [PubMed: 24686827]
16. Rabadi MH, Mayanna SK, Vincent AS. Predictors of mortality in veterans with traumatic spinal cord injury. *Spinal Cord.* 2013; 51:784–88. [PubMed: 23896672]
17. Sabre L, Rekan T, Asser T, Korv J. Mortality and causes of death after traumatic spinal cord injury in Estonia. *J Spinal Cord Med.* 2013; 36(6):687–94. [PubMed: 24090049]
18. Whiteneck GG, Charlifue SW, Frankel HL, Fraser MH, Gardner BP, Gerhart KA, et al. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. *Paraplegia.* 1992; 30:617–30. [PubMed: 1408338]
19. Nash MS, Tractenberg RE, Mendez AJ, David M, Ljungberg IH, Tinsley EA, et al. Cardiometabolic syndrome in people with spinal cord injury/disease: guideline derived and nonguideline risk components in a pooled sample. *Arch Phys Med Rehabil.* 2016; 97:1696–705. [PubMed: 27465752]
20. Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. *J Formosa Med Assoc.* 2007; 106:919–28.
21. Huang CC, Liu CW, Weng MC, Chen TW, Huang MH. Association of C-reactive protein and insulin resistance in patients with chronic spinal cord injury. *J Rehabil Med.* 2008; 40:819–22. [PubMed: 19242618]
22. Liang H, Mojtahedi MC, Chen D, Braunschweig CL. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury. *Arch Phys Med Rehabil.* 2008; 89:36–41. [PubMed: 18164328]
23. Gibson AE, Buchholz AC, Ginis KM. C-Reactive protein in adults with chronic spinal cord injury: increased chronic inflammation in tetraplegia vs paraplegia. *Spinal Cord.* 2008 Sep 1; 46(9):616–21. [PubMed: 18414426]
24. Laughton GE, Buchholz AC, Ginis KM, Goy RE. Lowering body mass index cutoffs better identifies obese persons with spinal cord injury. *Spinal cord.* 2009 Oct 1; 47(10):757–62. [PubMed: 19350042]
25. Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR, et al. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. *Arch Phys Med Rehabil.* 2008; 89:726–31. [PubMed: 18374004]
26. Kirshblum SC, Waring W, Biering-Sorensen F, Burns SP, Johansen M, Schmidt-Read M, et al. Reference for the 2011 revision of the International Standards for Neurological Classifications of Spinal Cord Injury. *J Spinal Cord Med.* 2011; 34:547–54. [PubMed: 22330109]
27. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir Dis.* 1978; 188:1–120.
28. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clinical Infectious Diseases.* 2005:643–54. [PubMed: 15714408]
29. Jones LM, Legge M, Goulding A. Healthy body mass index values often underestimate body fat in men with spinal cord injury. *Arch Phys Med Rehabil.* 2003; 84:1068–71. [PubMed: 12881836]
30. Ciriigliaro CM, LaFountaine MF, Dengel DR, Bosch TA, Emmons RR, Kirshblum SC, et al. Visceral adiposity in persons with chronic spinal cord injury determined by dual energy x-ray absorptiometry. *Obesity.* 2015; 23:1811–17. [PubMed: 26239944]

31. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. *JAMA*. 2006; 295:1412–19. [PubMed: 16551713]
32. Aarabi G, Eberhard J, Reissmann D, Heydecke G, Seedorf U. Interaction between periodontal disease and atherosclerotic vascular disease - Fact or fiction? *Atherosclerosis*. 2015; 241(2):555–560. [PubMed: 26100678]
33. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case control studies. *Heart*. 2015; 101:1738–1747. [PubMed: 26310262]
34. Sims JB, de Lemos JA, Maewal P, Warner JJ, Peterson GE, McGuire DK. Urinary tract infection in patients with acute coronary syndrome: a potential systemic inflammatory connection. *Am Heart J*. 2005; 149(6):1062–65. [PubMed: 15976789]

TABLE 1

## Locomotive Mode and Participant Characteristics (N=338)

Characteristics	Motorized wheelchair (n=64)	Hand propelled wheelchair (n=150)	Walks with an aid (n=57)	Walks without assistance (n=67)	Total (n=338)
CRP (mg/L) [median, 25%ile, 75%ile]	4.57 (2.71, 11.47)	2.55 (1.15, 7.18)	1.70 (0.85, 6.67)	1.42 (0.51, 2.91)	2.54 (1.04, 7.09)
Age (yrs) [mean, SD]	53.3±14.7	49.0±13.3	62.7±13.1	58.9±12.6	54.1±14.4
Injury Duration (yrs) [mean, SD]	17.2±15.2	17.7±12.0	18.7±15.3	15.5±12.3	17.3±13.3
BMI (kg/m <sup>2</sup> ) [mean, SD]	27.5±6.3	26.2±6.1	29.8±5.4	27.5±6.0	27.3±6.1
<b>Percent fat</b> [mean, SD]					
Android region, % fat	44.6±11.0	42.6±13.0	43.5±11.0	38.4±13.7	42.3±12.6
Gynoid region, % fat	44.6±8.8	41.8±9.5	37.8±9.3	33.8±8.7	40.1±9.9
Trunk region, % fat	42.6±9.4	39.9±11.4	39.9±9.6	35.1±11.7	39.4±11.0
Total body, % fat	40.5±7.5	36.8±9.0	35.9±8.1	31.6±8.6	36.3±8.9
<b>Race</b>	<b>[n, %]</b>	<b>[n, %]</b>	<b>[n, %]</b>	<b>[n, %]</b>	<b>[n, %]</b>
White	56 (87.5)	132 (88.0)	47 (82.5)	57 (85.1)	292 (86.4)
Black	7 (10.9)	9 (6.0)	8 (14.0)	5 (7.5)	29 (8.6)
Other	1 (1.6)	9 (6.0)	2 (3.5)	5 (7.5)	17 (5.0)
<b>Sex</b>					
Female	17 (26.6)	24 (16.0)	8 (14.0)	11 (16.4)	60 (17.8)
Male	47 (73.4)	126 (84.0)	49 (86.0)	56 (83.6)	278 (82.3)
<b>SCI Classification</b>					
Motor complete cervical & AIS C	43 (67.2)	36 (24.0)	1 (1.8)	0 (0.0)	80 (23.7)
Motor complete high thoracic* & AIS C	8 (12.5)	38 (25.3)	0 (0.0)	0 (0.0)	46 (13.6)
Other motor complete & AIS C	4 (6.3)	58 (38.7)	5 (8.8)	1 (1.5)	68 (20.1)
All AIS D	9 (14.1)	18 (12.0)	51 (89.5)	66 (98.5)	144 (42.6)
<b>BMI (kg/m<sup>2</sup>)</b>					
Normal (<25)	20 (31.3)	68 (45.3)	13 (22.8)	23 (34.3)	124 (36.7)
Overweight (25 bmi < 30)	21 (32.8)	47 (31.3)	20 (35.1)	25 (37.3)	113 (33.4)
Obese ( ≥ 30)	23 (35.9)	35 (23.3)	24 (42.1)	19 (28.4)	101 (29.9)
<b>Skin Ulcers</b>					
Now	15 (23.4)	21 (14.0)	2 (3.5)	0 (0.0)	38 (11.2)

Characteristics	Motorized wheelchair (n= 64)	Hand propelled wheelchair (n=150)	Walks with an aid (n=57)	Walks without assistance (n=67)	Total (n=338)
In the past year	31 (48.4)	49 (32.7)	3 (5.3)	2 (3.0)	85 (25.2)
In the past 3 years	36 (56.3)	64 (42.7)	6 (10.5)	2 (3.0)	108 (32.0)
<b>Urinary Tract Infections</b>					
Now	10 (15.6)	13 (8.7)	1 (1.8)	1 (1.5)	25 (7.4)
In the past year	45 (70.3)	100 (66.7)	12 (21.1)	6 (9.0)	163 (48.2)
In the past 3 years	56 (87.5)	105 (70.0)	20 (35.1)	18 (26.9)	199 (58.9)
<b>Use of urinary catheter</b>					
No catheter use	11 (17.2)	31 (20.7)	44 (77.2)	61 (91.0)	147 (43.5)
Yes catheter use	53 (82.8)	119 (79.3)	13 (22.8)	6 (9.0)	191 (56.5)
Periodic catheterization	15 (23.4)	79 (52.7)	10 (17.5)	5 (7.5)	109 (32.3)
Chronic catheter	33 (51.6)	17 (11.3)	1 (1.8)	1 (1.5)	52 (15.4)
Condom catheter	5 (7.8)	23 (15.3)	2 (3.5)	0 (0.0)	30 (8.9)
<b>Statin use</b>	14 (21.9)	39 (26.0)	24 (42.1)	31 (46.3)	108 (32.0)
<b>Heart disease</b>	5 (7.8)	9 (6.0)	21 (36.8)	4 (6.0)	39 (11.5)
<b>Hypertension</b>	14 (21.9)	43 (28.7)	36 (63.2)	31 (46.3)	124 (36.7)
<b>Diabetes</b>	6 (9.4)	17 (11.3)	15 (26.3)	12 (17.9)	50 (14.8)
<b>Regular dental care</b>	40 (62.5)	98 (65.3)	32 (56.1)	35 (52.2)	205 (60.7)
<b>Chest illness in past year</b>	11 (17.2)	15 (10.0)	6 (10.5)	9 (13.4)	41 (12.1)
<b>Chest illness in past 3 years (n=337)</b>	22 (34.4)	32 (21.3)	12 (21.4)	16 (23.9)	82 (24.3)
<b>Respiratory illness in past 1 week (n=336)</b>					
No respiratory illness	63 (100.0)	137 (92.0)	51 (89.5)	59 (88.1)	310 (92.3)
Mild cold** or other respiratory illness	0 (0.0)	12 (8.0)	6 (10.5)	8 (11.9)	26 (7.7)
<b>COPD</b>					
Asthma	5 (7.8)	10 (6.7)	8 (14.0)	11 (16.4)	34 (10.1)
<b>COPD or asthma</b>	10 (15.6)	14 (9.3)	10 (17.5)	11 (16.4)	45 (13.3)
<b>Cigarette Use</b>	14 (21.9)	22 (14.7)	16 (28.1)	19 (28.4)	71 (21.0)
Current	11 (17.2)	22 (14.7)	11 (19.3)	15 (22.4)	59 (17.5)
Former	24 (37.5)	52 (34.7)	31 (54.4)	34 (50.8)	141 (41.7)
Pack years (n=200 ever smokers) [median, 25%ile,75%ile]	20 (9.0, 38.0)	12.8 (3.5, 26.0)	25 (11.0, 39.0)	26.5 (9.2, 45.0)	18.3 (5.1, 38.0)
Never	29 (45.3)	76 (50.7)	15 (26.3)	18 (26.9)	138 (40.8)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Characteristics	Motorized wheelchair (n= 64)	Hand propelled wheelchair (n=150)	Walks with an aid (n=57)	Walks without assistance (n=67)	Total (n=338)
	0 (0.0)	7 (4.7)	5 (8.8)	4 (6.0)	16 (4.8)

\* high thoracic= T11- T6

\*\*\* Mild cold

TABLE 2

Univariable associations with ln CRP (mg/L; N=338)

Clinical factors, continuous covariates	e( $\beta$ )	e(95% CI)	p-value
Age (yrs)	1.00	0.99, 1.01	0.960
Injury Duration (yrs)	1.00	0.99, 1.01	0.689
Pack Years	1.00	1.00, 1.01	0.165
Clinical factors, categorical covariates	e(ln mean CRP)	e (95% CI)	p
<b>Sex</b>			0.374
Female	2.27	1.59, 3.25	
Male	2.71	2.30, 3.20	
<b>Race</b>			0.038
White	2.47	2.10, 2.90	
Non-white	3.92	2.61, 5.89	
<b>SCI Classification</b>			p-trend<0.001
Motor complete cervical & AIS C	4.02	2.97, 5.43	
Motor complete high thoracic * & AIS C	3.57	2.40, 5.31	
Other motor complete & AIS C	3.00	2.16, 4.16	
All AIS D	1.77	1.41, 2.21	
<b>Mobility mode</b>			p-trend<0.001
Motorized wheelchair	5.53	3.98, 7.68	
Hand propelled wheelchair	2.79	2.25, 3.45	
Walk with aid	2.22	1.56, 3.14	
Walk without assistance	1.31	0.95, 1.81	
<b>Skin Ulcers</b>			
Now	2.40	2.05, 2.81	<0.001
None now	5.38	3.45, 8.37	
In the past year	4.03	2.99, 5.41	0.001
None in the past year	2.28	1.92, 2.71	
In the past 3 years	3.85	2.96, 5.01	0.001
None in the past 3 years	2.28	1.84, 2.63	
<b>Uses urinary catheter</b>			
Yes	3.67	3.02, 4.45	<0.001 **
Periodic catheterization	3.36	2.60, 4.34	
Chronic catheter	4.55	3.14, 6.59	
Condom catheter	3.48	2.14, 5.67	
No	1.70	3.02, 4.45	
<b>Urinary Tract Infections (UTIs)</b>			
Now	4.94	2.85, 8.56	0.020
None now	2.50	2.14, 2.92	
In the past year	3.61	2.86, 4.56	<0.001
None in the past year	2.12	1.75, 2.57	

Clinical factors, continuous covariates	e( $\beta$ )	e(95% CI)	p-value
In the past 3 years	2.93	2.41, 3.56	0.094
None in the past 3 years	2.26	1.78, 2.85	
<b>Current statin use</b>			0.166
Yes	2.25	1.73, 2.94	
No	2.83	2.36, 3.39	
<b>Regular dental care</b>			0.894
Yes	2.61	2.09, 3.39	
No	2.66	2.15, 3.17	
<b>Chest illness in the past year</b>			0.807
Yes	2.50	1.62, 3.85	
No	2.65	2.25, 3.11	
<b>Chest illness in the past 3 years (n=337)</b>			0.184
Yes	3.14	2.31, 4.26	
No	2.47	2.08, 2.94	
<b>Respiratory illness in the past week (n=336)</b>			0.096
Yes	4.10	2.28, 5.01	
No	2.54	2.14, 2.97	
<b>Heart disease</b>			0.325
Yes	3.24	2.08, 5.05	
No	2.56	2.18, 3.00	
<b>COPD</b>			0.351
Yes	2.12	1.32, 3.41	
No	2.69	2.30, 3.16	
<b>Ashma</b>			0.958
Yes	2.60	1.72, 3.93	
No	2.63	2.24, 3.10	
<b>Doctor diagnosed COPD or asthma</b>			0.417
Yes	2.33	1.68, 3.24	
No	2.71	2.29, 3.22	
<b>Diabetes</b>			0.518
Yes	2.96	2.00, 4.38	
No	2.58	2.19, 3.03	
<b>Hypertension</b>			0.378
Yes	2.87	2.24, 3.69	
No	2.50	2.07, 3.02	
<b>Smoking Status</b>			0.751
Current	2.95	2.06, 4.24	
Former	2.63	2.08, 3.33	
Never	2.50	1.97, 3.17	

\* high thoracic=T1-T6

\*\* Catheter/no catheter



**TABLE 3**

Associations between measures of body fat and natural log CRP (mg/L; N=338)

Fat predictor	BMI (kg/m <sup>2</sup> )			DXA - Total body % fat			DXA - Trunk % fat			DXA - Android % fat			DXA - Gynoid % fat		
	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value
	<b>1.80</b>	<b>1.48, 2.19</b>	<b>&lt;0.001</b>	<b>2.28</b>	<b>1.90, 2.73</b>	<b>&lt;0.001</b>	<b>2.16</b>	<b>1.82, 2.57</b>	<b>&lt;0.001</b>	<b>2.15</b>	<b>1.78, 2.59</b>	<b>&lt;0.001</b>	<b>1.93</b>	<b>1.58, 2.36</b>	<b>&lt;0.001</b>
<b>Quartiles</b>	<b>e<sup>(ln mean CRP)</sup></b>	<b>e<sup>(95% CI)</sup></b>	<b>p-value</b>	<b>e<sup>(ln mean CRP)</sup></b>	<b>e<sup>(95% CI)</sup></b>	<b>p-value</b>	<b>e<sup>(ln mean CRP)</sup></b>	<b>e<sup>(95% CI)</sup></b>	<b>p-value</b>	<b>e<sup>(ln mean CRP)</sup></b>	<b>e<sup>(95% CI)</sup></b>	<b>p-value</b>	<b>e<sup>(ln mean CRP)</sup></b>	<b>e<sup>(95% CI)</sup></b>	<b>p-value</b>
Quartile 1 (lowest)	1.56	1.16, 2.09	p-trend<0.001	1.12	0.85, 1.46	p-trend<0.001	1.12	0.86, 1.46	p-trend<0.001	1.23	0.94, 1.62	p-trend<0.001	1.32	1.00, 1.75	p-trend<0.001
Quartile 2	2.11	1.58, 2.81		2.15	1.63, 2.83		2.15	1.65, 2.81		1.92	1.46, 2.53		2.29	1.70, 3.10	
Quartile 3	3.39	2.53, 4.55		3.58	2.73, 4.71		3.27	2.49, 4.29		3.48	2.64, 4.60		3.97	2.99, 5.27	
Quartile 4 (highest)	4.33	3.24, 5.79		5.74	4.36, 7.56		6.56	4.98, 8.64		5.82	4.43, 7.66		3.93	2.97, 5.21	
Quartile 1	<22.8		31			33			35		33				33
Quartile 2	22.8	x<27.0	31<x	37		343<x	41		35<x	45		33<x	41		41
Quartile 3	27.0	x<31.2	37<x	43		41<x	47		45<x	52		41<x	47		47
Quartile 4	31.2		>43			>47			>52		>47		>47		>47

TABLE 4

Multivariable associations with natural log CRP (mg/L; N=336)

Fat measures	BMI (kg/m <sup>2</sup> )			DXA - Total body % fat			DXA - Trunk % fat			DXA - Android % fat			DXA - Gynoid % fat		
	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI<sup>†</sup>QOR)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI<sup>†</sup>QOR)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value
	<b>1.84</b>	<b>1.53, 2.21</b>	<b>&lt;0.001</b>	<b>2.06</b>	<b>1.71, 2.47</b>	<b>&lt;0.001</b>	<b>1.99</b>	<b>1.68, 2.35</b>	<b>&lt;0.001</b>	<b>1.98</b>	<b>1.66, 2.37</b>	<b>&lt;0.001</b>	<b>1.66</b>	<b>1.35, 2.05</b>	<b>&lt;0.001</b>
<b>Other clinical factors</b>	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value	e <sup>(ln mean CRP)</sup>	e <sup>(95% CI)</sup>	p-value
Ulcer(s) now	5.35	3.33, 8.59	0.096	5.64	3.55, 8.94	0.167	5.51	3.49, 8.72	0.154	5.41	3.41, 8.60	0.173	5.98	3.68, 9.71	0.130
No ulcer(s) now	3.70	2.76, 4.96		4.18	3.14, 5.56		4.06	3.06, 5.39		4.02	3.02, 5.36		4.23	3.13, 5.72	
Urinary catheter	5.62	3.86, 8.18	0.009	6.30	4.37, 9.08	0.003	6.18	4.30, 8.88	0.002	6.07	4.21, 8.75	0.003	6.33	4.31, 9.29	0.013
No urinary catheter	3.52	2.43, 5.09		3.73	2.61, 5.35		3.62	2.53, 5.18		3.59	2.50, 5.15		4.00	2.74, 5.84	
Respiratory illness in the past 1 week	6.13	3.63, 10.35	0.012	6.69	4.02, 11.14	0.010	6.40	3.86, 10.62	0.015	6.39	3.83, 10.66	0.012	7.26	4.25, 12.42	0.005
No respiratory illness in the past 1 week	3.22	2.49, 4.17		3.52	2.74, 4.53		3.50	2.73, 4.49		3.41	2.65, 4.38		3.48	2.67, 4.54	
White	3.63	2.64, 4.99	0.041	3.56	2.61, 4.85	0.001	3.51	2.58, 4.78	0.002	3.55	2.60, 4.85	0.005	3.87	2.79, 5.35	0.010
Non-white	5.45	3.52, 8.43		6.62	4.33, 10.12		6.37	4.18, 9.71		6.12	4.00, 9.37		6.55	4.19, 10.23	
Mobility mode			p-trend<0.001			p-trend=0.069			p-trend=0.013			p-trend=0.003			p-trend=0.018
Motorized wheelchair	8.36	5.37, 12.99		6.83	4.41, 10.57		7.31	4.75, 11.24		7.74	5.01, 11.93		7.80	4.94, 12.31	
Hand propelled wheelchair	4.61	3.20, 6.63		4.31	3.02, 6.15		4.22	2.97, 6.01		4.22	2.95, 6.03		4.33	2.98, 6.29	
Walk with aid	3.66	2.32, 5.75		4.73	3.06, 7.33		4.44	2.88, 6.84		4.27	2.76, 6.62		5.06	3.20, 8.02	
Walk without assistance	2.78	1.77, 4.35		3.98	2.56, 6.20		3.66	2.36, 5.66		3.40	2.19, 5.28		3.75	2.35, 5.99	